NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Zinc Ahead Ltd | Veeva Systems

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments - European research association establishing technology foundation for greater efficiency and speed across research projects - Lymphoma-Research-Experts.org / Veeva.com
LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments

 

NewswireTODAY - /newswire/ - Pleasanton, CA, United States, 2022/01/20 - European research association establishing technology foundation for greater efficiency and speed across research projects - Lymphoma-Research-Experts.org / Veeva.com. NYSE: VEEV

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Veeva Systems today announced that the Lymphoma Academic Research Organization (LYSARC) selected Veeva Development Cloud to improve operational efficiency across its lymphoma therapy research. LYSARC will use applications in Vault Clinical, Vault Quality, and Vault Safety suites to build a robust, connected technology foundation that enables faster execution, higher quality data, and better trial oversight.

“Partnering with Veeva will accelerate our digital transformation for greater scalability and speed in our pursuit to develop innovative lymphoma therapies or improve current therapies,” said Franck Morschhauser, president of LYSARC. “Using Veeva Development Cloud gives us a single connected platform that can free our staff from time-consuming tasks and allow them to focus on what drives us every day: scientific excellence for the benefit of lymphoma patients.”

The largest European academic organization devoted to lymphoma clinical research, LYSARC recruits more than 750 patients every year across Belgium, France, and Portugal. To expand its reach, the organization is collaborating with other academic groups in Europe or abroad, in partnership with pharma companies, and needed technology that can scale with its growth.

Veeva Development Cloud will bring together clinical, quality, and safety operations for end-to-end business processes and execution. With a digital and unified systems landscape, LYSARC can improve the patient trial experience, ensure alignment with SOPs across stakeholders, and reduce the costs and lead times of clinical trials.

“LYSARC is fully invested in empowering its teams with advanced technologies to evolve how they work together in a complex environment,” said Jim Reilly, vice president of Vault R&D and Quality at Veeva Systems. “We’re proud to work with an organization dedicated to innovation, and we look forward to supporting their development of new lymphoma research and therapies.”

LYSARC, the operational structure of the cooperative group LYSA, is standardizing clinical processes with Vault CDMS, Vault CTMS, Vault eTMF, Vault Study Start-up, and Vault Payments, streamlining quality processes with Vault QMS, Vault QualityDocs, and Vault Training, and mitigating risk with Vault Safety. The organization will also encourage its network of partners to adopt Veeva SiteVault Free to enable seamless information sharing with site investigators and sponsors.

About LYSA: a network of clinical research professionals

LYSA is a cooperative, academic group, and a non-profit organization, an international leader in clinical research and translational on lymphomas. It groups together more than 500 medical members, researchers, and experts distributed over 90 clinical centers in three countries (France, Belgium, and Portugal). LYSA’s aim is to assemble professionals, who specialize in the field of lymphomas, to promote basic and clinical research, improve prevention, the care and treatment of patients, and promulgate knowledge about this cancer. It collaborates with numerous scientific teams around the world in the understanding and treatment of lymphomas.

LYSARC: the academic research organization linked to LYSA

LYSARC (lymphoma-research-experts.org) is LYSA’s operational body, allowing the conduct of clinical research on lymphomas at the international level. LYSARC has available to it all those integrated functions and platforms devoted to the pathology, biology, and imaging tests to run multiple clinical studies of phases 1 to 4 on lymphomas every year and registers in its role as promotor. This non-profit organization is scientifically independent and pools more than 130 highly qualified staff (doctors, pharmacists, biologists, engineers, and MBAs).

About Veeva Systems

Veeva (veeva.com) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.

Contact: Kiran May
P: +44(0)79 6643 2912 - E: kiran.may[.]veeva.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Zinc Ahead Ltd | Veeva Systems

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
LYSA LYSARC | Veeva Systems, Inc.
Contact: Deivis Mercado - Veeva.com 
925-226-8821 deivis.mercado[.]veeva.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Zinc Ahead Ltd | Veeva Systems securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Zinc Ahead Ltd | Veeva Systems / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

NEC Selected by AMED for Design of A Universal Vaccine that is Effective Against Influenza Virus Strains
BostonGene, NEC and JIP Form Joint Venture in Japan
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib
US FDA Approves Ipsen’s Sohonos™ (palovarotene) Capsules, the First and Only Treatment for People with Fibrodysplasia Ossificans Progressiva
SCHOTT Pharma Strengthens Leading Position in the First Year as Stand-alone Company
Frost & Sullivan Awarded Duopharma Biotech with the 2022 Malaysian Company of the Year Award
Duopharma Biotech Applauded by Frost & Sullivan for Providing Innovative Healthcare Solutions in the Malaysian Market
Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP
U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome
DNAnexus® Applauded by Frost & Sullivan for Supporting Better Clinical Decision-making and More Effective Therapies
Ipsen to Present New Bylvay® (odevixibat) Data At ESPGHAN Congress, Showcasing Commitment to Furthering Treatment for Rare Cholestatic Liver Diseases
SCHOTT Pharma Launches Prefillable Syringes (PFS) for Deep-cold Drugs
ANDRITZ Introduces Comprehensive Solutions to Produce Alternative Proteins
DSM Agrees Terms to Acquire Postbiotics Pioneer Adare Biome
NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented At AACR 2023

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2023 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)